LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI…
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the…
Practice patterns for sequential use of antibody-drug conjugate after antibody-drug
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
ERG: New Gene Linked to Blood Disorders and Hematologic Cancers [ASH 2023]
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology…
Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023]
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the…
Managing High-Risk Hematologic Malignancies in the Community [ASH 2023]
Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How…
Where do you see the greatest utility of ctDNA testing in patients with solid tumors?
In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…